Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,accountsPayable,otherLiab,netReceivables,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToNetincome,capitalExpenditures,otherCashflowsFromFinancingActivities,changeToAccountReceivables,WC,language,region,quoteType,triggerable,quoteSourceName,currency,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,exchange,exchangeDataDelayedBy,marketState,twoHundredDayAverageChangePercent,shortName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,market,priceHint,regularMarketChangePercent,regularMarketDayRange,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jul 29, 2021) 4","Short Ratio (Jul 29, 2021) 4","Short % of Float (Jul 29, 2021) 4","Short % of Shares Outstanding (Jul 29, 2021) 4","Shares Short (prior month Jun 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry
t0,ENLV,90206000.0,18305800,2539000,,-3108000,,-3108000,1269000,0,-3808000,-3808000,,-495000,,,,0,0,3808000,0,700000,,-3108000,-3108000,131663000.0,4981000.0,90206000.0,793000.0,95187000.0,2104000.0,883000.0,-43805000.0,244000.0,94000.0,12612000.0,4576000.0,244000.0,2265000.0,92828000.0,77988000.0,558000.0,,,12501000.0,202000.0,12202000.0,2000.0,-1138000.0,2000.0,8183000.0,389000.0,-4410000.0,122000.0,-488000.0,-299000.0,,,88252000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,13.86,12.6,12.8,9,8,finmb_84011067,NasdaqCM,Enlivex Therapeutics Ltd.,USD,313845,270650,8.1299,1.7750874,4.58 - 29.4,-16.6901,-0.5676905,4.58,29.4,1551830400,-0.985,-1.6,-0.86,-14.778954,4.95,9.067778,3.6421223,0.40165544,10.721594,1.988306,232664880,-7.9436874,2.5676568,15,America/New_York,EDT,-14400000,False,False,NCM,0,REGULAR,0.18544874,Enlivex Therapeutics Ltd.,12.7099,1630509242,-1.1500998,13.63,13.7,12.4201,163492,us_market,2,-8.297978,12.4201 - 13.7,0.24,,,29.4,4.58,9.07,10.72,313.85k,270.65k,18.31M,,13.74M,21.93%,13.58%,141.61k,2.64,0.83%,0.77%,140.42k,,,,,,0.00%,"Mar 05, 2019",,1:8,"Mar 05, 2019","Dec 30, 2020","Jun 29, 2021",0.00%,0.00%,-12.69%,-23.75%,,,,,-12.86M,-14.3M,-0.99,,90.6M,4.95,615k,0.68,20.29,4.95,-14.86M,-6.59M,Value,7403618,Healthcare,50,"Enlivex Therapeutics Ltd. operates as a clinical stage immunotherapy company. It is developing Allocetra, an off-the-shelf cell therapy designed to reprogram macrophages into homeostatic state. Resetting non-homeostatic macrophages into homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. Diseases, such as solid cancers, sepsis, COVID-19, and others reprogram macrophages out of homeostatic state. Its Allocetra has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents. The company has a research collaboration with Yale Cancer Center for the assessment of Allocetra to enhance the activity of checkpoint inhibitors in solid tumors. Enlivex Therapeutics Ltd. was incorporated in 2005 and is headquartered in Nes Ziona, Israel.",Ness Ziona,972 8 662 3301,1577750400,Israel,http://www.enlivex.com,86400,14 Einstein Street,972 8 631 2981,Biotechnology
t-1,ENLV,90605000.0,18305800,2497000,,-3200000,,-3200000,1305000,0,-3802000,-3802000,,-495000,,,,0,0,3802000,0,602000,,-3200000,-3200000,131009000.0,5357000.0,90605000.0,1146000.0,95962000.0,2104000.0,1225000.0,-40697000.0,-1811000.0,91000.0,4089000.0,4908000.0,-1811000.0,2095000.0,93776000.0,87577000.0,347000.0,,,-59416000.0,-101000.0,-59589000.0,60916000.0,990000.0,65371000.0,-1612000.0,-599000.0,-2340000.0,117000.0,-146000.0,-173000.0,-4455000.0,,88868000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,13.86,12.6,12.8,9,8,finmb_84011067,NasdaqCM,Enlivex Therapeutics Ltd.,USD,313845,270650,8.1299,1.7750874,4.58 - 29.4,-16.6901,-0.5676905,4.58,29.4,1551830400,-0.985,-1.6,-0.86,-14.778954,4.95,9.067778,3.6421223,0.40165544,10.721594,1.988306,232664880,-7.9436874,2.5676568,15,America/New_York,EDT,-14400000,False,False,NCM,0,REGULAR,0.18544874,Enlivex Therapeutics Ltd.,12.7099,1630509242,-1.1500998,13.63,13.7,12.4201,163492,us_market,2,-8.297978,12.4201 - 13.7,0.24,,,29.4,4.58,9.07,10.72,313.85k,270.65k,18.31M,,13.74M,21.93%,13.58%,141.61k,2.64,0.83%,0.77%,140.42k,,,,,,0.00%,"Mar 05, 2019",,1:8,"Mar 05, 2019","Dec 30, 2020","Jun 29, 2021",0.00%,0.00%,-12.69%,-23.75%,,,,,-12.86M,-14.3M,-0.99,,90.6M,4.95,615k,0.68,20.29,4.95,-14.86M,-6.59M,Value,7403618,Healthcare,50,"Enlivex Therapeutics Ltd. operates as a clinical stage immunotherapy company. It is developing Allocetra, an off-the-shelf cell therapy designed to reprogram macrophages into homeostatic state. Resetting non-homeostatic macrophages into homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. Diseases, such as solid cancers, sepsis, COVID-19, and others reprogram macrophages out of homeostatic state. Its Allocetra has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents. The company has a research collaboration with Yale Cancer Center for the assessment of Allocetra to enhance the activity of checkpoint inhibitors in solid tumors. Enlivex Therapeutics Ltd. was incorporated in 2005 and is headquartered in Nes Ziona, Israel.",Ness Ziona,972 8 662 3301,1577750400,Israel,http://www.enlivex.com,86400,14 Einstein Street,972 8 631 2981,Biotechnology
t-2,ENLV,35487000.0,18305800,2152000,,-5864000,,-5864000,1545000,0,-3697000,-3697000,,-2392000,,,,0,0,3697000,0,-2167000,,-5864000,-5864000,70361000.0,4871000.0,35487000.0,1171000.0,40358000.0,1646000.0,1250000.0,-37497000.0,977000.0,97000.0,5673000.0,4372000.0,977000.0,2140000.0,38121000.0,30034000.0,288000.0,499000.0,,-3958000.0,98000.0,-4439000.0,10529000.0,1401000.0,10736000.0,615000.0,284000.0,-5759000.0,361000.0,-66000.0,-481000.0,-207000.0,-1689000.0,33749000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,13.86,12.6,12.8,9,8,finmb_84011067,NasdaqCM,Enlivex Therapeutics Ltd.,USD,313845,270650,8.1299,1.7750874,4.58 - 29.4,-16.6901,-0.5676905,4.58,29.4,1551830400,-0.985,-1.6,-0.86,-14.778954,4.95,9.067778,3.6421223,0.40165544,10.721594,1.988306,232664880,-7.9436874,2.5676568,15,America/New_York,EDT,-14400000,False,False,NCM,0,REGULAR,0.18544874,Enlivex Therapeutics Ltd.,12.7099,1630509242,-1.1500998,13.63,13.7,12.4201,163492,us_market,2,-8.297978,12.4201 - 13.7,0.24,,,29.4,4.58,9.07,10.72,313.85k,270.65k,18.31M,,13.74M,21.93%,13.58%,141.61k,2.64,0.83%,0.77%,140.42k,,,,,,0.00%,"Mar 05, 2019",,1:8,"Mar 05, 2019","Dec 30, 2020","Jun 29, 2021",0.00%,0.00%,-12.69%,-23.75%,,,,,-12.86M,-14.3M,-0.99,,90.6M,4.95,615k,0.68,20.29,4.95,-14.86M,-6.59M,Value,7403618,Healthcare,50,"Enlivex Therapeutics Ltd. operates as a clinical stage immunotherapy company. It is developing Allocetra, an off-the-shelf cell therapy designed to reprogram macrophages into homeostatic state. Resetting non-homeostatic macrophages into homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. Diseases, such as solid cancers, sepsis, COVID-19, and others reprogram macrophages out of homeostatic state. Its Allocetra has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents. The company has a research collaboration with Yale Cancer Center for the assessment of Allocetra to enhance the activity of checkpoint inhibitors in solid tumors. Enlivex Therapeutics Ltd. was incorporated in 2005 and is headquartered in Nes Ziona, Israel.",Ness Ziona,972 8 662 3301,1577750400,Israel,http://www.enlivex.com,86400,14 Einstein Street,972 8 631 2981,Biotechnology
t-3,ENLV,28499000.0,18305800,1202000,,-2125000,,-2125000,757000,0,-1959000,-1959000,,-223000,,,,0,0,1959000,0,-166000,,-2125000,-2125000,59820000.0,4873000.0,28499000.0,1999000.0,33372000.0,1513000.0,2144000.0,-31633000.0,-1201000.0,110000.0,4148000.0,4374000.0,-1201000.0,1656000.0,31606000.0,24028000.0,334000.0,,717000.0,-4000000.0,-191000.0,-4372000.0,10529000.0,-414000.0,10736000.0,-6495000.0,230000.0,-2353000.0,72000.0,256000.0,-372000.0,-207000.0,49000.0,27232000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,13.86,12.6,12.8,9,8,finmb_84011067,NasdaqCM,Enlivex Therapeutics Ltd.,USD,313845,270650,8.1299,1.7750874,4.58 - 29.4,-16.6901,-0.5676905,4.58,29.4,1551830400,-0.985,-1.6,-0.86,-14.778954,4.95,9.067778,3.6421223,0.40165544,10.721594,1.988306,232664880,-7.9436874,2.5676568,15,America/New_York,EDT,-14400000,False,False,NCM,0,REGULAR,0.18544874,Enlivex Therapeutics Ltd.,12.7099,1630509242,-1.1500998,13.63,13.7,12.4201,163492,us_market,2,-8.297978,12.4201 - 13.7,0.24,,,29.4,4.58,9.07,10.72,313.85k,270.65k,18.31M,,13.74M,21.93%,13.58%,141.61k,2.64,0.83%,0.77%,140.42k,,,,,,0.00%,"Mar 05, 2019",,1:8,"Mar 05, 2019","Dec 30, 2020","Jun 29, 2021",0.00%,0.00%,-12.69%,-23.75%,,,,,-12.86M,-14.3M,-0.99,,90.6M,4.95,615k,0.68,20.29,4.95,-14.86M,-6.59M,Value,7403618,Healthcare,50,"Enlivex Therapeutics Ltd. operates as a clinical stage immunotherapy company. It is developing Allocetra, an off-the-shelf cell therapy designed to reprogram macrophages into homeostatic state. Resetting non-homeostatic macrophages into homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. Diseases, such as solid cancers, sepsis, COVID-19, and others reprogram macrophages out of homeostatic state. Its Allocetra has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents. The company has a research collaboration with Yale Cancer Center for the assessment of Allocetra to enhance the activity of checkpoint inhibitors in solid tumors. Enlivex Therapeutics Ltd. was incorporated in 2005 and is headquartered in Nes Ziona, Israel.",Ness Ziona,972 8 662 3301,1577750400,Israel,http://www.enlivex.com,86400,14 Einstein Street,972 8 631 2981,Biotechnology
